Cancer therapeutics encompasses a range of treatment modalities, including chemotherapy, immunotherapy, targeted therapy, and combination regimens designed to eradicate malignant cells (Cancer.gov.). Targeted therapies, such as tyrosine kinase inhibitors, offer precision approaches that interfere with specific molecular pathways involved in tumor growth (Verywell Health). Our contributions focus on identifying novel inhibitors that improve efficacy and reduce off‑target effects in clinically relevant cancer models (Cancer.gov ).
Photodynamic therapy (PDT) is a minimally invasive, two‑stage treatment that combines light, oxygen, and photosensitizing agents to generate reactive oxygen species (ROS) that selectively destroy cancerous and precancerous cells. PDT offers high spatial precision and reduced systemic toxicity compared to conventional modalities. Recent advances leverage novel photosensitizers, smart nanoplatforms, supramolecular assemblies, and combination strategies (e.g., immunotherapy, radiotherapy) to enhance efficacy, overcome hypoxia, and enable theranostic applications (MDPIPMC).
Protein kinases regulate critical cell signaling processes, and dysregulation of kinase activity is a hallmark of many cancers (PMC). Kinase inhibitors have transformed oncology by selectively blocking aberrant signaling pathways, with over 25 kinase‑targeted drugs approved to date (PMC). Our research aims to design novel kinase inhibitors with improved selectivity profiles to overcome resistance mechanisms and minimize toxicity (Nature).
Cancer stem cells (CSCs) constitute a subpopulation of tumor cells with self‑renewal capacity and contribute to relapse and metastasis PMC. Fluorescent probes like AldeRed™ enable the detection of CSCs by targeting aldehyde dehydrogenase activity, facilitating flow cytometry‑based isolation MilliporeSigma. Your work involves developing next‑generation molecular probes for more sensitive and specific identification of CSCs in heterogeneous tumor samples PMC.
Antiviral drug discovery focuses on identifying compounds that inhibit virus replication or modulate host factors essential to the viral life cycle (Nature). Recent advances leverage high‑throughput screening and structure‑based design to target viral enzymes and host proteins( RSC Publishing). Your research explores novel scaffolds to inhibit emerging viral pathogens with an emphasis on broad‑spectrum activity and reduced resistance potential (PMC).